Molecular remission and non-Hodgkin's lymphoma
Molecular remission and non-Hodgkin's lymphoma
Non-Hodgkin's lymphomas are highly sensitive to treatment and complete clinical responses are often achieved. However, disease recurrence is common and is caused by the persistence of malignant lymphoma cells at a level below the limits of detection by conventional assessment such as clinical examination, bone marrow morphology and CT scans. This minimal residual disease can be detected using molecular techniques such as the polymerase chain reaction (PCR), and treatments capable of eliminating minimal residual disease are described as producing molecular remission. Molecular assessment is now commonly used as a measure of outcome in clinical trials of novel therapies for the treatment of lymphoma. The evidence for using molecular remission as a surrogate marker of clinical response in this setting is reviewed and the significance of minimal residual disease in determining prognosis and planning treatment strategies is addressed.
non-hodgkin's lymphoma, follicular lymphoma, mantle-cell lymphoma, minimal residual disease, bcl-2, chromosomal translocation, polymerase chain reaction, immunoglobulin rearrangement
549-562
Darby, Angela J.
37bf05d2-0075-4a39-9825-988680e8dcab
Johnson, Peter W.M.
1a86c9a9-25b4-4529-9353-d14fd062d63b
2002
Darby, Angela J.
37bf05d2-0075-4a39-9825-988680e8dcab
Johnson, Peter W.M.
1a86c9a9-25b4-4529-9353-d14fd062d63b
Darby, Angela J. and Johnson, Peter W.M.
(2002)
Molecular remission and non-Hodgkin's lymphoma.
Best Practice & Research: Clinical Haematology, 15 (3), .
(doi:10.1053/beha.2002.0216).
Abstract
Non-Hodgkin's lymphomas are highly sensitive to treatment and complete clinical responses are often achieved. However, disease recurrence is common and is caused by the persistence of malignant lymphoma cells at a level below the limits of detection by conventional assessment such as clinical examination, bone marrow morphology and CT scans. This minimal residual disease can be detected using molecular techniques such as the polymerase chain reaction (PCR), and treatments capable of eliminating minimal residual disease are described as producing molecular remission. Molecular assessment is now commonly used as a measure of outcome in clinical trials of novel therapies for the treatment of lymphoma. The evidence for using molecular remission as a surrogate marker of clinical response in this setting is reviewed and the significance of minimal residual disease in determining prognosis and planning treatment strategies is addressed.
This record has no associated files available for download.
More information
Published date: 2002
Keywords:
non-hodgkin's lymphoma, follicular lymphoma, mantle-cell lymphoma, minimal residual disease, bcl-2, chromosomal translocation, polymerase chain reaction, immunoglobulin rearrangement
Identifiers
Local EPrints ID: 26273
URI: http://eprints.soton.ac.uk/id/eprint/26273
PURE UUID: 300e260f-398a-40f2-bc20-c1772abe79fb
Catalogue record
Date deposited: 21 Apr 2006
Last modified: 15 Mar 2024 07:09
Export record
Altmetrics
Contributors
Author:
Angela J. Darby
Author:
Peter W.M. Johnson
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics